These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 18298578)

  • 1. Pneumococcal pneumonia in HIV-infected patients by antiretroviral therapy periods.
    Saindou M; Chidiac C; Miailhes P; Voirin N; Baratin D; Amiri M; Livrozet JM; Touraine JL; Trepo C; Peyramond D; Vanhems P
    HIV Med; 2008 Apr; 9(4):203-7. PubMed ID: 18298578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumonia in HIV-infected patients in the HAART era: incidence, risk, and impact of the pneumococcal vaccination.
    López-Palomo C; Martín-Zamorano M; Benítez E; Fernández-Gutiérrez C; Guerrero F; Rodríguez-Iglesias M; Girón-González JA
    J Med Virol; 2004 Apr; 72(4):517-24. PubMed ID: 14981752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
    Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
    Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era.
    Madeddu G; Porqueddu EM; Cambosu F; Saba F; Fois AG; Pirina P; Mura MS
    Infection; 2008 Jun; 36(3):231-6. PubMed ID: 18463787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence rate and risk factors for loss to follow-up in HIV-infected patients from five French clinical centres in Northern France - January 1997 to December 2006.
    Ndiaye B; Ould-Kaci K; Salleron J; Bataille P; Bonnevie F; Choisy P; Cochonat K; Fontier C; Guerroumi H; Ajana F; Chaud P; Yazdanpanah Y
    Antivir Ther; 2009; 14(4):567-75. PubMed ID: 19578242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.
    Martínez E; Milinkovic A; Buira E; de Lazzari E; León A; Larrousse M; Loncá M; Laguno M; Blanco JL; Mallolas J; García F; Miró JM; Gatell JM
    HIV Med; 2007 May; 8(4):251-8. PubMed ID: 17461853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival in HIV-infected patients is associated with hepatitis C virus infection and injecting drug use since the use of highly active antiretroviral therapy in the Lyon observational database.
    Voirin N; Trépo C; Miailhes P; Touraine JL; Chidiac C; Peyramond D; Livrozet JM; Ritter J; Chevallier P; Fabry J; Allard R; Vanhems P
    J Viral Hepat; 2004 Nov; 11(6):559-62. PubMed ID: 15500557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Ocular manifestations in patients with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy].
    Mesarić B; Lisić M; Kniewald T; Ugrinović N; Begovac J
    Lijec Vjesn; 2005; 127(5-6):123-8. PubMed ID: 16281473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors.
    Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S
    Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
    Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
    Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.
    León A; Martinez E; Milinkovic A; Mora B; Mallolas J; Blanco JL; Larrousse M; Laguno M; Gallart T; Plana M; Gatell JM; Garcia F
    J Antimicrob Chemother; 2009 Jan; 63(1):184-8. PubMed ID: 19001447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial pneumonia in HIV-infected patients: use of the pneumonia severity index and impact of current management on incidence, aetiology and outcome.
    Curran A; Falcó V; Crespo M; Martinez X; Ribera E; Villar del Saz S; Imaz A; Coma E; Ferrer A; Pahissa A
    HIV Med; 2008 Oct; 9(8):609-15. PubMed ID: 18557951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Invasive pneumococcal disease in a cohort of HIV-infected adults: incidence and risk factors, 1990-2003.
    Barry PM; Zetola N; Keruly JC; Moore RD; Gebo KA; Lucas GM
    AIDS; 2006 Feb; 20(3):437-44. PubMed ID: 16439878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-HAART tuberculosis in adults and adolescents with HIV in India: incidence, clinical and immunological profile.
    Rajasekaran S; Raja K; Jeyaseelan L; Vijilat S; Priya K; Mohan K; Parvez A; Mahilmaran A; Chandrasekar C
    Indian J Tuberc; 2009 Apr; 56(2):69-76. PubMed ID: 19810588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome and prognosis factors in HIV-infected hemodialysis patients.
    Tourret J; Tostivint I; du Montcel ST; Bragg-Gresham J; Karie S; Vigneau C; Guiard-Schmid JB; Deray G; Bagnis CI
    Clin J Am Soc Nephrol; 2006 Nov; 1(6):1241-7. PubMed ID: 17699354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of highly active antiretroviral therapy on incidence of early syphilis in HIV-infected patients.
    Park WB; Jang HC; Kim SH; Kim HB; Kim NJ; Oh MD; Choe KW
    Sex Transm Dis; 2008 Mar; 35(3):304-6. PubMed ID: 18157070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 infected patients older than 50 years. PISCIS cohort study.
    Navarro G; Nogueras MM; Segura F; Casabona J; Miro JM; Murillas J; Tural C; Ferrer E; Jaén A; Force L; Vilaró J; García I; Masabeu A; Altés J; Esteve A; Sued O; Riera M; Clotet B; Podzamczer D; Gatell JM;
    J Infect; 2008 Jul; 57(1):64-71. PubMed ID: 18572247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection.
    Powles T; Robinson D; Stebbing J; Shamash J; Nelson M; Gazzard B; Mandelia S; Møller H; Bower M
    J Clin Oncol; 2009 Feb; 27(6):884-90. PubMed ID: 19114688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients.
    Herida M; Mary-Krause M; Kaphan R; Cadranel J; Poizot-Martin I; Rabaud C; Plaisance N; Tissot-Dupont H; Boue F; Lang JM; Costagliola D
    J Clin Oncol; 2003 Sep; 21(18):3447-53. PubMed ID: 12972519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.